News

Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...
Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)
Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...
BioSpace5h
More Than a One Trick Pony, Lilly Feeds Success Back Into Biotech
On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play
According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...
Solar stocks, Eli Lilly & Verve, PureCycle: Trending Tickers
Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...
This Stock Just Jumped 77% After Eli Lilly Made an Agreed $1.3 Billion Bid
Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...